Bliss GVS Pharma share price
NSE: BLISSGVSBSE: 506197Pharmaceuticals & BiotechnologySmall Cap
Bliss GVS Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1985 on BSE, Jul 2010 on NSE
Last close ₹647.50down ₹33.40 (4.91%)BSE ₹648.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹680.90.
30 Oct: open ₹660.00, high ₹670.00, low ₹646.90
52-week range of traded prices to 30 Oct 2026
₹118.00Low, 10 Nov 2025₹739.90High, 28 Sep 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,885 Cr1,000th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 42.71
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.23%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,45,760
About Bliss GVS Pharma
Bliss GVS Pharma Limited, headquartered in Mumbai, manufactures and markets pharmaceutical formulations for international markets, including suppositories and pessaries (medicines placed in the rectum or vagina), capsules, tablets and syrups.1 Its R&D centre in Mumbai is certified by DSIR, India's Department of Scientific and Industrial Research.2
It was incorporated in 1984 and merged with GVS Labs in 2006.3 It has a presence in 60+ countries, and Sub-Saharan Africa, its largest market, accounted for more than 80% of its sales volume in the year to Mar 2026.45 It has 150+ brands, 50+ therapeutic segments and 16+ dosage forms (the forms a medicine takes, such as tablets or suppositories).6 Its major therapeutic segments are anti-malarials, anti-fungal and anti-bacterial, anti-inflammatory, analgesics (painkillers) with antipyretics (fever reducers), anti-infectives and women wellness.7 Its brands include Lonart, P-Alaxin and Gsunate, which are anti-malarial medicines.8 It makes its products at 6 manufacturing units in Palghar, Vevoor and Ambernath, Maharashtra.9 At 31 Mar 2026 it had 2 wholly owned subsidiaries, 1 partly owned subsidiary and 4 step-down subsidiaries (companies held through another subsidiary), and 1,033 permanent employees.1011
Since 28 Sep 2026, Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited have held control of the company and are its promoters.12 On 28 Sep 2026, together they held 47.95% of its equity share capital.13
Bliss GVS Pharma key points
Results
- In the year to Mar 2026, consolidated revenue was ₹9,271 million and the EBITDA margin was 18%, as the company presents them. EBITDA is earnings before interest, tax, depreciation and amortisation.14
- Consolidated profit before tax and exceptional items increased to ₹19,207.63 lakh from ₹12,563.92 lakh a year earlier, and consolidated net profit increased to ₹13,472.77 lakh from ₹9,025.53 lakh.15
- On a standalone basis (the company alone, without its subsidiaries), revenue in the year to Mar 2026 was approximately ₹7,298 million, up 9%.16
- In the year to Mar 2026, the company said its debtor days (the average days taken to collect payment from customers) fell to 188 days and its overall borrowings fell by 96%, a decrease of ₹680 million.17
Products and therapeutic areas
International business
- On a standalone basis (the company alone), it earned ₹66,348.16 lakh in foreign exchange (receipts in foreign currency) and spent ₹11,821.21 lakh in foreign exchange in the year to Mar 2026.20
- In the year to Mar 2026, its Singapore subsidiary incorporated 2 wholly owned subsidiaries: Theralife Pharma Ltd in Nairobi, Kenya, and Theralife Pharma RDC Private Limited in Kinshasa, Democratic Republic of the Congo.21
Plants and capacity
- Annual capacity of the main products by unit, in units per annum22
Unit 1, Palghar: tablets 450 million Unit 2, Palghar: suppositories and pessaries 380 million Unit 3, Palghar: suppositories and pessaries 576 million Unit 5, Vevoor: tablets 2,300 million Unit 5, Vevoor: capsules 1,800 million Unit 4, Vevoor: ointments, creams and gel 200 million Unit 6, Ambernath: ointments, creams and gel 90 million - The company lists accreditations (approvals from drug regulators) including US FDA, TGA Australia, EU GMP, FDA Russia and Health Canada, and 25+ others.23
- The company said it made progress on its facility for creams, ointments and gels at Vevoor, Palghar, and on expanding suppositories and pessaries manufacturing at Unit 2, with investments of approximately ₹69 crore in the year to Mar 2026.24
- The company has 9.6 MW of installed solar plants, which generated 13 million units of solar power in the year to Mar 2026.25
Research and development
- The company invested ₹189 million in research and development in the year to Mar 2026, and its R&D team has 85+ members.26
- The company is expanding its presence in regulated markets through in-house development, outsourced projects and technology transfer partnerships (moving a developed product's manufacturing to another site).27
What the company expects
- The company stated in its annual report for the year to Mar 2026 that it is executing capacity expansion on suppository lines and is strengthening its Africa business by widening its therapeutic portfolio.28
- The company stated in its annual report for the year to Mar 2026 that it is increasing sales in regulated markets by expanding its product filings and commercial strategies.29
Change of control
- On 23 May 2026, shareholders including promoters Narsimha Shibroor Kamath, Vibha Gagan Sharma and Shruti Vishal Rao signed a share purchase agreement to sell 4,58,03,024 equity shares, 43.30% of paid-up capital, to Anupam Rasayan India Limited.3031
- On 23 May 2026, the agreement required Anupam Rasayan India Limited to make an open offer (an offer to buy shares from public shareholders) for up to 26% of the company's total paid-up equity share capital on a fully diluted basis.3230
- In its filing of 22 Jul 2026, the company said the open offer, made by Anupam Rasayan India Limited together with Mates Visa Consultancy Private Limited, was for up to 2,77,26,848 equity shares, 26.00% of the expanded voting share capital.33
- On 28 Sep 2026, the company said 1669 equity shares were acquired under the open offer, and Mates Visa Consultancy Private Limited, to which Anupam Rasayan assigned its rights under the agreement on 17 Jul 2026, completed the purchase of 5,09,84,595 equity shares.34
Recent events
- On 28 Sep 2026, Narsimha Shibroor Kamath resigned as Managing Director, and Hetul Krishnakant Mehta, Amar Dilip Shah and Pramod Badrinarayan Kasat were appointed additional non-executive non-independent directors.35
- On 12 May 2026, the board recommended a final dividend of ₹1.00 per equity share for the year to Mar 2026, after an interim dividend of ₹0.50 per share paid to shareholders on record on 18 Feb 2026.36
- On 8 Apr 2026, ICRA, a credit rating agency (which gives an opinion on ability to repay debt), assigned ratings of [ICRA]A- (Stable) long term and [ICRA]A2+ short term to the company's fund-based and non-fund-based facilities (loans and guarantees) of ₹100.00 crore.3738
Last updated
All 38 sources, each with its page
- 1. Annual report, 23 Jun 2026, page 57
- 2. Annual report, 23 Jun 2026, page 13
- 3. Annual report, 23 Jun 2026, page 7
- 4. Annual report, 23 Jun 2026, page 58
- 5. Annual report, 23 Jun 2026, page 33
- 6. Annual report, 23 Jun 2026, page 11
- 7. Annual report, 23 Jun 2026, page 9
- 8. Annual report, 23 Jun 2026, page 19
- 9. Annual report, 23 Jun 2026, page 12
- 10. Annual report, 23 Jun 2026, page 34
- 11. Annual report, 23 Jun 2026, page 47
- 12. Exchange filing, 28 Sep 2026, page 1
- 13. Exchange filing, 28 Sep 2026, page 1
- 14. Annual report, 23 Jun 2026, page 6
- 15. Annual report, 23 Jun 2026, page 33
- 16. Annual report, 23 Jun 2026, page 6
- 17. Annual report, 23 Jun 2026, page 6
- 18. Annual report, 23 Jun 2026, page 9
- 19. Annual report, 23 Jun 2026, page 11
- 20. Annual report, 23 Jun 2026, page 48
- 21. Annual report, 23 Jun 2026, page 34
- 22. Annual report, 23 Jun 2026, page 12
- 23. Annual report, 23 Jun 2026, page 12
- 24. Annual report, 23 Jun 2026, page 6
- 25. Annual report, 23 Jun 2026, page 11
- 26. Annual report, 23 Jun 2026, page 13
- 27. Annual report, 23 Jun 2026, page 13
- 28. Annual report, 23 Jun 2026, page 58
- 29. Annual report, 23 Jun 2026, page 58
- 30. Exchange filing, 23 May 2026, page 1
- 31. Exchange filing, 23 May 2026, page 2
- 32. Exchange filing, 23 May 2026, page 2
- 33. Exchange filing, 22 Jul 2026, page 1
- 34. Exchange filing, 28 Sep 2026, page 1
- 35. Exchange filing, 28 Sep 2026, page 2
- 36. Annual report, 23 Jun 2026, page 34
- 37. Exchange filing, 8 Apr 2026, page 1
- 38. Exchange filing, 8 Apr 2026, page 2
Results
Consolidated; ₹ crore.Bliss GVS Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +24.9%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +47.0%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹313 Crup 9.73%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹53 Crup 3.83%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 17.0%
Revenue by quarter
Peak revenue ₹313 Cr, quarter to Sep 2026; lowest ₹198 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 210 | 198 | 207 | 244 | 218 | 257 | 286 | 313 |
| Net profit | 26 | 17 | 44 | 29 | 25 | 37 | 51 | 53 |
| Net margin | 12.3% | 8.4% | 21.4% | 11.7% | 11.4% | 14.4% | 18.0% | 17.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹927 Crup 14.50%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹135 Crup 49.27%
- Net margin
- 14.5%
Revenue by year
Peak revenue ₹927 Cr, year to Mar 2026; lowest ₹577 Cr, year to Mar 2021
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 800 | 815what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹0.50 crore, a tax on the goods the company makes that it collects and pays to the government. | 898 | 689 | 577 | 747 | 752 | 770 | 810 | 927 |
| Net profit | 86 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 135 |
| Net margin | 10.7% | 10.9% | 14.1% | 13.8% | 12.8% | 3.1% | 10.2% | 10.6% | 11.1% | 14.5% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical & Healthcare, which carries all its revenue.
Valuation
Today, against the company's own history.Bliss GVS Pharma PE ratio and valuation
Price to earnings
At or below today's level on 97% of 2,192 trading days over the last 10 years.
LowestHighest
Its median14.66Industry median27.65
Price to book
At or below today's level on 98% of 1,978 trading days since Nov 2018.
LowestHighest
Its median1.44Industry median2.88
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 2% of 2,426 trading days over the last 10 years.
LowestHighest
Its median0.44%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +83.7% | +52.5% | +20.0% | 0.7% |
| 3 years | +45.2% | +21.4% | +19.2% | 0.5% |
| 5 years | +17.5% | +13.0% | +3.5% | 0.6% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 2 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 1,835 | 0.29% | ₹0.13 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 865 | 0.29% | ₹0.06 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 2 Nov 2025.Bliss GVS Pharma insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group3 purchases, 2 sales₹0.25 Cr₹6.92 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹6.67 Cr1 pledge created
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Bliss GVS Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Bliss GVS Pharma in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Symbiotec PharmalabSYMBIOTEC | 8,008 | – | – | – | – | – | – | 0.00% |
 Sanofi Consumer Healthcare IndiaSANOFICONR | 7,928 | 28.34 | 22.79 | +22.7% | +28.4% | 92.5% | 102.5% | 2.18% |
 Aarti PharmalabsAARTIPHARM | 7,914 | – | 3.51 | +13.4% | – | – | 11.9% | 0.40% |
 Sanofi IndiaSANOFI | 7,379 | 20.24 | 8.93 | −5.7% | +2.3% | 45.3% | 57.3% | 3.84% |
 Supriya LifescienceSUPRIYA | 6,819 | 34.38 | 5.69 | +28.1% | +11.4% | 18.1% | 21.6% | 0.12% |
 Morepen LaboratoriesMOREPENLAB | 6,211 | 32.94 | 4.50 | +30.2% | +91.2% | 14.6% | 14.3% | 0.18% |
 FDCFDC | 6,138 | 19.59 | 2.30 | +10.2% | +39.0% | 12.3% | 11.5% | 1.33% |
 Innova CaptabINNOVACAP | 5,867 | 37.54 | 5.43 | +34.5% | +20.4% | 15.3% | 15.0% | 0.20% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Bliss GVS Pharma dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.50 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 8 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.00 |
| 18 Feb 2026 | Interim | ₹0.50 |
| 24 Jul 2025 | Final | ₹0.50 |
| 18 Jul 2024 | Final | ₹0.50 |
| 12 Jul 2023 | Final | ₹0.50 |
| 20 Jun 2022 | Final | ₹0.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Bliss GVS Pharma announcements
Oct 2026
29 Oct · Results
15 Oct · Disclosure
Bliss GVS Pharma share price by year
Each calendar year to 2025.Bliss GVS Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 163.39 | −0.8% | 183.17 | 111.84 |
| 2024 | 164.71 | +32.1% | 176.25 | 97.65 |
| 2023 | 124.65 | +72.2% | 146.35 | 70.45 |
| 2022 | 72.40 | −30.2% | 103.70 | 66.90 |
| 2021 | 103.70 | −48.7% | 206.40 | 92.35 |
| 2020 | 202.15 | +34.1% | 205.40 | 93.05 |
| 2019 | 150.70 | −8.7% | 182.15 | 81.90 |
| 2018 | 165.00 | −22.2% | 213.45 | 127.05 |
| 2017 | 212.00 | +36.1% | 215.65 | 144.15 |
| 2016 | 155.75 | −11.5% | 183.05 | 80.65 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 29 Oct 2026 | 667.95 | 680.90 | 652.75 | 680.90 | 678.86 | 4,47,694 |
| 28 Oct 2026 | 642.00 | 654.40 | 625.00 | 648.50 | 642.57 | 1,51,133 |
| 27 Oct 2026 | 618.20 | 640.00 | 613.00 | 639.25 | 631.37 | 85,958 |
| 26 Oct 2026 | 620.00 | 635.00 | 605.10 | 620.05 | 616.66 | 2,48,332 |
| 23 Oct 2026 | 645.10 | 659.00 | 615.00 | 623.35 | 633.09 | 1,58,050 |
| 22 Oct 2026 | 612.00 | 642.70 | 599.00 | 642.70 | 636.38 | 2,46,146 |
| 21 Oct 2026 | 627.05 | 633.00 | 597.20 | 612.10 | 614.06 | 2,75,925 |
| 19 Oct 2026 | 662.50 | 662.50 | 620.00 | 627.05 | 637.80 | 1,18,223 |
| 16 Oct 2026 | 651.00 | 658.00 | 640.00 | 652.00 | 649.14 | 1,29,277 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Open offer history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 15 Mar 2021 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 28 Feb 2020 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 3 Aug 2009 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 26 Sep 2008 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 11 Mar 2008 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- BLISSGVS
- BSE code
- 506197
- ISIN
- INE416D01022
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.blissgvs.com
- CIN
- L24230MH1984PLC034771
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1984
- Registered office
- 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai 400072, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments